A Real-world Study Of Yiqi Huayu Jiedu Decoction Combined With TACE (Transhepatic Artery Infusion Chemoembolization) In The Treatment Of Advanced Primary Liver Cancer

Objective: In this study,a real-world study was conducted on the treatment of advanced primary liver cancer with the combination of Yiqi Huayu Jiedu Prescription and TACE(transcatheter arterial chemoembolization)to preliminarily evaluate the clinical efficacy of this regimen and provide scientific evidence for clinical practice.Methods: The cases were from inpatients admitted to the oncology department of the affiliated hospital of hunan traditional Chinese medicine institute and the interventional department of xiangya hospital from January 2016 to September 2019,according to inclusion and exclusion criteria,a total of 104 patients were included,the experimental group was treated with TACE combined with Yiqi Huayu Jiedu Prescription,and the control group was treated with TACE alone.The PFS,tumor,TCM syndromes,quality of life,safety and hospitalization costs of patients in the two groups were evaluated,by constructing a single-factor analysis model and a risk model for each factor affecting survival,the different benefits of patients’ survival under the influence of different factors were analyzed.Results:(1)After treatment,ALT,AST,TBIL and AFP in the experimental group decreased significantly compared with the control group(P<0.01).(2)The disease control rate of the two groups in the objective efficacy evaluation of the tumor was better in the experimental group than in the control group(P<0.0 5).(3)KPS and TCM syndrome scores in the experimental group between pre and post treatment were significantly improved compared with the control group(P<0.01).(4)The mean PFS of the experimental group was(218.679 ±166.014)d,and the mean PFS of the control group was(155.292 ±131.320)d,and the difference between the two groups was statistically significant(P<0.05).Single-factor analysis showed that liver function grade and age were related to tumor progression (P<0.05).Treatment mode was the main factor affecting PFS in HCC patients(P<0.05).(5)The incidence of adverse reactions such as abdominal pain,abdominal distension,nausea and vomiting,and hepatotoxicity after treatment in the experimental group was lower than that in the control group(P<0.01).The hospital stay of TACE treatment alone was shorter,but the cost was significantly higher than that of TACE treatment combined with Yiqi Huayu Jiedu Prescription(P<0.01).Conclusion:Yiqi Huayu Jiedu Prescription combined with TACE for the treatment of primary liver cancer can stabilize the tumor,prolong the PFS,improve the clinical symptoms and quality of life of patients,reduce the level of AFP,reduce the occurrence of toxic and side effects,and reduce the economic burden of patients,which is worthy of clinical promotion.